Repaglinide
Versus Metformin in Combination With Bedtime NPH
Combined
with bedtime NPH insulin, metformin provides superior
glycemic control to repaglinide.
The
study comapred the effect on glycemic control and weight
gain of repaglinide versus metformin combined with bedtime NPH
insulin in patients with type 2 diabetes.
A
total of 80 subjects treated with 850 or 1,000 mg t.i.d.
metformin combined with bedtime NPH insulin were randomized
to 13 weeks of open-label treatment with 4 mg t.i.d.
repaglinide (n = 39) or metformin (dose unchanged) (n
= 41). Insulin dose was titrated at the clinician’s discretion,
aiming for a fasting blood glucose (FBG)
6.0
mmol/l.
The
study shoed that baseline age, diabetes duration, insulin requirement,
weight, BMI, FBG, and HbA1c (Diabetes Control and
Complications Trial–aligned assay, normal range
4.6–6.2%) were similar. Glycemic control improved (nonsignificantly)
with insulin/metformin by (mean) 0.4%, from 8.4 to 8.1% but
deteriorated with insulin/repaglinide by (mean) 0.4%, from
8.1 to 8.6%. Weight gain was less with insulin/metformin:
0.9 ± 0.4 kg (means ± SE) versus 2.7 ± 0.4 kg (P <
0.0001).
From
the results, it was concluded that, combined with bedtime NPH insulin,
metformin provides superior glycemic control to repaglinide
with less weight gain and improved diabetes treatment
satisfaction. Diabetes Care 25:1685-1690,
2002
================================
FACT
Americans
are eating an average of 400 calories more than they did decades ago
-- at that rate an average person can expect to gain 41.7 pounds a
year. NIH
================================
Let
your Patients Enjoy low carb chocolates with no sugar and 1gm of
carbohydrate:
http://www.rx4betterhealth.com/catalog10_0.html
